

BBS-Bioactive Bone Substitutes Plc: Notification pursuant to the Finnish Securities Market Act, Chapter 9, Section 10 - Finha Capital Oy

BBS-Bioactive Bone Substitutes Plc | Company Release | June 18, 2024 at 15:00:00 EEST

BBS-Bioactive Bone Substitutes Plc has on June 18, 2024 received a notification in accordance with the Finnish Securities Market Act, according to which the holdings of shares and votes of Finha Capital Oy in BBS-Bioactive Bone Substitutes Plc have before April 19, 2024 crossed the threshold of 10%. The reason for the flagging notification is the amendment to the Finnish Securities Market Act, which expanded the flagging obligation to companies listed on the Nasdaq First North Growth Market Finland.

Total position of Finha Capital Oy according to the notification:

	% of shares and voting rights	% of shares and voting rights through financial instruments	Total of both in %	Total number of shares and voting rights of the issuer
Resulting situation on the date on which threshold was crossed or reached	11.62%	0%	11.62%	20,297,175
Position of previous notification (if applicable)				

Notified details of the resulting situation on the date on which the threshold was crossed:

Class/type of shares ISIN code	Number of shares and voting rights		% of shares and voting rights	
	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)
FI4000260583	2,357,965		11.62%	0%
SUBTOTAL	2,357,965		11.62%	

After April 19, 2024, Finha Capital Oy holds 11.62% of the shares and votes.

For more information, please contact:

Juliusz Rakowski, CEO

+358 50 448 5132

juliusz.rakowski@bbs-artebone.fi

Certified Advisor:

Nordic Certified Adviser AB,

+46 70 551 67 29,

info@certifiedadviser.se



Company Release
18 June 2024 15:00:00 EEST

Distribution

Nasdaq Helsinki

<https://www.bbs-artebone.fi/>

BBS in brief

BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi